People: argenx SE (ARGX.OQ)
Dr. David L. Lacey serves as Non-Executive Independent Member of the Board at argenx SE. He was Member of the Supervisory Board of arGEN-X BV since July 2014. Dr. Lacey is a biopharmaceutical consultant at David L. Lacey LLC, where he advises academic institutions, biotechnology companies and venture capital firms, a position he has held since July 2011. He currently serves as a director of Inbiomotion SL, Atreca, Inc. and Nurix, Inc. From 1994 until his retirement in 2011, he held various positions, including head of discovery research, at Amgen Inc., where he played a fundamental scientific role in the discovery of the OPG/ RANKL/RANK pathway, which led to the development of the anti- RANKL human mAb denosumab, for both osteoporosis (Prolia) and cancer-related bone diseases (XGEVA). He holds a Bachelor’s degree in biology and an M. D. from the University of Colorado, and has his board certification in anatomic pathology. He is the chairman of Research and Development committee.
|Total Annual Compensation, EUR||606,537|
|Restricted Stock Award, EUR||--|
|Long-Term Incentive Plans, EUR||--|
|All Other, EUR||--|
|Fiscal Year Total, EUR||606,537|